The conjugated estrogen/bazedoxifene tissue-selective estrogen complex (TSEC) is designed to minimize the undesirable effects of estrogen in the uterus and breast tissues and to allow the beneficial effects of estrogen in other estrogen-target tissues, such as the bone and brain. However, the molecular mechanism underlying endometrial and breast safety during TSEC use is not fully understood. Estrogen receptor a (ERa)-estrogen response element (ERE)-DNA pull-down assays using HeLa nuclear extracts followed by mass spectrometry-immunoblotting analyses revealed that, upon TSEC treatment, ERa interacted with transcriptional repressors rather than coactivators. Therefore, the TSEC-mediated recruitment of transcriptional repressors suppresses ERa-mediated transcription in the breast and uterus. In addition, TSEC treatment also degraded ERa protein in uterine tissue and breast cancer cells, but not in bone cells. Interestingly, ERa-ERE-DNA pull-down assays also revealed that, upon TSEC treatment, ERa interacted with the F-box protein 45 (FBXO45) E3 ubiquitin ligase. The loss-of-and gain-of-FBXO45 function analyses indicated that FBXO45 is involved in TSEC-mediated degradation of the ERa protein in endometrial and breast cells. In preclinical studies, these synergistic effects of TSEC on ERa inhibition also suppressed the estrogen-dependent progression of endometriosis. Therefore, the endometrial and breast safety effects of TSEC are associated with synergy between the selective recruitment of transcriptional repressors to ERa and FBXO45-mediated degradation of the ERa protein.
Introduction
Estrogen receptors (ERs) are members of the nuclear receptor superfamily of ligand-inducible transcription factors that regulate essential cellular processes, such as development, metabolism, reproduction, and behavior, by regulating the transcription of ER target genes ). The working model for ERa action indicates that ligand-bound receptor binds to the enhancers/promoters of target genes that contain the estrogen-response element and sequentially recruits multiple coregulator complexes to these regulatory regions; this results in chromatin remodeling and assembly of the transcriptional preinitiation complex as well as the downstream processing events involved in mRNA synthesis and maturation (McKenna and O'Malley, 2002; Green and Carroll, 2007; Foulds et al., 2013) .
Because of its essential role in estrogen target tissues, aberrant regulation of the ERa level and activity is associated with estrogen-related progression of human disease (Deroo and Korach, 2006; . Therefore, the development of tissue-specific modulators of ERa activity is a critical step to effectively treat the estrogen-related disease progression in specific tissues while minimizing side effects in certain other tissues. This goal led to the development of selective estrogenreceptor modulators (SERMs) (Levenson and Jordan, 1999) . The SERMs act as tissue-specific estrogen-receptor agonists in the bone, brain, cardiovascular system, vagina, and urogenital system and as estrogen-receptor antagonists in the breast, endometrium, pelvic floor, and in venous thrombosis (Morello et al., 2002; Maximov et al., 2013) . The first generation of SERMs included the drug tamoxifen (Ward, 1973; Jordan and Koerner, 1975) . Clinical studies revealed that treatment with tamoxifen significantly reduced the incidence of breast cancer in high-risk patients (Jordan, 1988; Morello et al., 2003) . However, chronic tamoxifen treatment has stimulatory effects on endometrial cells, increasing the risk of development and progression of endometrial cancer (Rutqvist, 1993; Iqbal et al., 2012) . To overcome the undesirable side effects of tamoxifen, raloxifene (second-generation SERM) was developed (Black et al., 1994) . Because raloxifene reduced the incidence of invasive breast cancer in postmenopausal women with osteoporosis, raloxifene is the current preferred drug for women at risk for vertebral fracture who have an elevated risk of breast cancer (Ko and Jordan, 2011; Gizzo et al., 2013) . Unlike tamoxifen, raloxifene does not increase the risk of uterine cancers (Vogel et al., 2006; DeMichele et al., 2008; Pinkerton and Goldstein, 2010) , even when combined with vaginal estrogen (Parsons et al., 2003; Pinkerton et al., 2003) . To improve upon the beneficial effects of raloxifene, thirdgeneration SERMs were developed, including bazedoxifene (BAZ), which prevented and treated postmenopausal osteoporosis without adverse stimulation of the breast and endometrium (Komm and Chines, 2012) .
To maximize the tissue-specific effects of SERMs and minimize their side effects, a tissue-selective estrogen complex (TSEC) has been developed (Archer, 2010; Pickar and Mirkin, 2010) . The final goal of TSEC therapy is to combine the desired tissue-selective properties of SERMs with the beneficial effects of estrogen. The TSEC would ideally have estrogen-receptor antagonist activity in the breast and endometrium, reduced vasomotor symptoms, and improved lipid profile and bone mineral density compared with a SERM-or estrogen-alone treatment (Mirkin et al., 2014) . The first-generation TSEC was a combination of BAZ and conjugated estrogen (CE), which had unique molecular properties compared with the individual components (Mirkin et al., 2014) . For example, the BAZ/CE TSEC combination was associated with a less than 1% rate of endometrial hyperplasia. This rate was not significantly different from a placebo-treated group during a 2-year study . When the incidence of uterine bleeding in postmenopausal women was studied, the mean number of bleeding or spotting days in women treated with TSEC was not significantly different from a placebo-treated group during 2 years of therapy (Archer et al., 2009 ). Thus, TSEC therapy can be used to treat menopausal symptoms without stimulation of the endometrium. Treatment with TSEC for 24 months also did not affect the mammographic density of postmenopausal women with breast cancer compared with a placebo-treated group (Harvey et al., 2013) . Therefore, the endometrial and breast-cell stimulatory effects of the accompanying CE were completely abrogated by BAZ in TSEC treatment (Song et al., 2013) . Collectively, the TSEC has an antiestrogenic effect on the growth of breast cancer cells and prevents the development of endometrial hyperplasia in postmenopausal women. However, the molecular mechanisms underlying endometrial and breast safety during TSEC administration are not understood yet; elucidation of these mechanisms is important for the use of TSEC in future clinical therapy. Here, we analyze the molecular functions of TSEC and suggest dual mechanisms by which TSEC inhibits ERa function in endometrial and breast cells.
Materials and Methods
Experimental Animals. Wild-type (C57BL/6J) mice were used. All experiments involving animals were conducted in accordance with the National Institutes of Health standards for the use and care of animals, with protocols approved by Baylor College of Medicine. C57BL/6J mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA).
Cell Culture and Reagents. The HeLa human cervical carcinoma, MCF7 human breast cancer, and HTB-85 human osteosarcoma cell lines were obtained from the American Type Culture Collection (Manassas, VA). HeLa cells were cultured in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal bovine serum (FBS). MCF7 cells were maintained in minimum essential medium supplemented with 10% FBS. HTB-85 cells were cultured in DMEM containing 10% FBS. 4-Hydroxytamoxifen, Carbobenzoxy-Leu-Leuleucinal (MG132), and ethanol-soluble estrogen (E2) were purchased from Sigma-Aldrich (St. Louis, MO). Bazedoxifene and CE (Premarin) were obtained from Pfizer Inc. (New York, NY). For cell culture, a mixture of the unconjugated forms of the 10 most abundant CE components of CE (Premarin; Pfizer Inc.) was prepared using the same relative proportions as the previously described CE formulation (Chang et al., 2010) , and a 1 mM CE stock solution was prepared using 1 mM solutions of each of the 10 components mixed according to their respective proportions.
Western Blot Analysis. Primary antibodies against the following proteins were used: SRC-1 (Abcam, Cambridge, MA), SRC-2 (Bethyl Laboratories, Montgomery, TX), SRC-3 (BD Biosciences, San Jose, CA), tubulin (Santa Cruz Biotechnologies, Dallas, TX), F-box protein 45 (FBXO45; Novus Biologicals, Littleton, CO), ERa (SC-542; Santa Cruz Biotechnologies), and BCL-6 corepressor (BCOR; Bethyl Laboratories). Membranes containing proteins were incubated with secondary horseradish peroxidase-tagged antibodies (SigmaAldrich), and the signals were visualized using ECL plus (Amersham, Pittsburgh, PA).
Immunohistochemistry. Immunostaining was performed with 10% neutral-buffered, formalin-fixed, and paraffin-embedded sections of mouse tissue. Antibodies against FBXO45 (Novus Biologicals), ERa (Santa Cruz Biotechnologies), and Ki-67 (Abcam) were used. The specific antigens were visualized with the DAB substrate kit (Vector Laboratories, Burlingame, CA). The immunostaining intensity was quantified using the ImageJ program, which was developed by the National Institutes of Health. Scale bar is 20 mm.
Uterotrophic Assay. Uterotrophic assays were performed to screen for potential estrogenic activity. CE, BAZ, and TSEC were administered daily via subcutaneous injection in 6-week-old ovariectomized female mice. Ovariectomy was performed as previously described (Han et al., 2005) . The animals were dosed for 3 consecutive days and necropsied approximately 24 hours after the final dose to determine wet and blotted uterine weights.
Estrogen Response Element-DNA Pull-Down Assays. The estrogen response element (ERE)-DNA pull-down reaction conditions and generation of biotinylated EREs were described previously (Foulds et al., 2013) . In brief, 4 mg of ERE DNA, 1 mg of HeLa nuclear extract, 0.5 mg of recombinant human ERa protein (Abcam), and 60 ml of Dynabeads M-280 Streptavidin were mixed with NETN (0.5% Nonyl Phenoxypolyethoxylethanol (NP)-40, 1 mM EDTA, 50 mM TrisHCl (PH7.5) and 150 mM NaCl) buffer and then incubated with vehicle, 10 nM CE, 100 nM BAZ, and 10 nM CE 1 100 nM BAZ (TSEC) at 4°C for 1.5 hours with constant shaking. The pellet was washed twice with NETN (0.5% NP40, 1 mM EDTA, 50 mM Tris-HCl (PH7.5) and 150 mM NaCl) buffer, 80% of the pellet was used for liquid chromatography mass spectroscopy (MS) analyses, and 20% was used for Western blotting analyses.
Protein Identification by MS. For MS analyses, nearly all of the ERE pull-down reaction (80%) was separated using one-dimensional SDS-PAGE. All ERa-interacting proteins were isolated from the gel, and their identities were determined by MS as described previously (Foulds et al., 2013) .
TSEC-Mediated ERa Degradation in Breast Cells. MCF7 breast cancer cells were cultured in six-well plates in duplicate and maintained in regular medium supplemented with 10% FBS. Prior to the experiment, the cells were deprived of estrogen for 2 days by incubating in stripped serum medium followed by treatment with Dual Inhibition of ERa by Tissue-Selective Estrogen Complex vehicle, 10 nM CE, 100 nM BAZ, 100 nM 4-hydroxytamoxifen (4-HT), 10 nM CE plus 100 nM BAZ (TSEC), and 10 nM CE plus 100 nM 4HT for 24 hours. The cells were then lysed, and the RNA and protein were extracted. For Western blotting analyses, the proteins were separated on a 10% SDS-PAGE gel, transferred into a nitrocellulose membrane, and incubated with anti-ERa and antitubulin antibodies overnight at 4°C followed by incubation with horseradish peroxidase-conjugated anti-rabbit antibody (Sigma-Aldrich) for 1 hour. Signals were detected using the ECL Plus system (Pierce, Waltham, Massachusetts). Transcript levels were analyzed by quantitative polymerase chain reaction using Applied Biosystems (Waltham, Massachusetts). cDNAs were synthesized, and TaqMan probes for ERa, progesterone receptor (PR), and 18S ribosomal RNA (rRNA; Applied Biosystems) were used to measure ERa, PR, and 18S rRNA levels. The quantitative polymerase chain reaction results were analyzed to determine the ratio of our target gene in our treated sample relative to our untreated sample using delta-delta cT method, and the fold enrichment was calculated relative to the 18S rRNA level.
Effect of FBXO45 Gain-of-Function and Loss-of-Function on ERa Stability. Knockdown experiments were performed in HeLa cells transfected with ERa by treating them with 100 nM nontargeting small interfering RNA (siRNA) or FBX045 (SMARTpool; Dharmacon, Lafayette, CO) siRNA for 48 hours. The cells were then incubated with vehicle, 10 nM CE, 100 nM BAZ, and 10 nM CE plus 100 nM BAZ (TSEC) for 24 hours. Cell lysates were prepared and used for Western blotting analyses with specific antibodies against FBX045 (Abcam), ERa, and tubulin. To examine the effect of FBXO45 gain-of-function, HeLa cells were transiently transfected with 100 ng each of ERa and FBXO45 expression vectors (gift from Hirobumi Tada, Keio University School of Medicine, Shinjuku, Tokyo, Japan) followed by treatment with vehicle, 10 nM CE, 100 nM BAZ, and 10 nM CE plus 100 nM BAZ (TSEC). Samples were collected at 0, 1, 3, 6, and 9 hours after treatment, and levels of ERa and FBXO45 were analyzed by Western blotting, as described earlier.
Coimmunoprecipitation and Western Blotting. For coimmunoprecipitation assays, HeLa cells were transiently transfected with 100 ng each of ERa and FBX045 expression vectors or empty vectors. After 48 hours, cells were treated with vehicle, 10 nM CE, 100 nM BAZ, and 10 nM CE plus 100 nM BAZ (TSEC) in the presence or absence of 10 mM MG132 for 6 hours. The lysates were incubated with ERa, Flag, or IgG antibodies under constant rotation. Protein G beads were added 2 hours later and incubated for an additional 2 hours, followed by extensive washing [20 mM HEPES (pH 7.6), 150 mM KCl, 1 mM Dithiothreitol, 0.1% NP40, and 8% glycerol supplemented with protease and phosphatase inhibitors]. The protein G beads were boiled in 1Â Laemmli buffer, and the coprecipitated proteins were separated by SDS-PAGE. The proteins were transferred onto nitrocellulose membranes, and Western blotting was performed and analyzed with specific antibodies.
Administration of CE, BAZ, and TSEC to Mice with Surgically Induced Endometriosis. The surgical treatments of mice were performed under aseptic conditions with anesthesia. Endometriosis was surgically induced in mice with a modification of a previously described method (Cummings and Metcalf, 1995) . In brief, 6-week-old C57BL/6 mice were ovariectomized. After 2 weeks, we implanted sterile 60-day-release pellets containing 0.36 mg of 17-b estradiol (Innovative Research of America, Sarasota, FL) into ovariectomized mice. Two days later, we isolated one uterine horn of each mouse under anesthesia. In a Petri dish containing warmed DMEM/F-12 (Invitrogen, Carlsbad , CA) supplemented with 100 U/ml penicillin and 100 mg/ml streptomycin, we longitudinally cut the uterine horns with a pair of scissors. We then isolated a tissue sample using a 2-mm dermal biopsy punch (Miltex, York, PA) and subsequently sutured one endometrial fragment to the mesenteric membrane attached to the intestine in the same mouse through a midline incision (7-0 braided silk suture; Ethicon). We closed the abdominal incision with a 5-0 braided silk suture (Ethicon, Blue Ash, OH) in a continuous fashion. Ectopic lesions were developed and established for 21 days after endometriosis induction. Subsequently, the mice were injected with vehicle, CE (2.5 mg/kg), BAZ (2.5 mg/kg), and TSEC (2.5 mg/kg CE plus 2.5 mg/kg BAZ) on alternate days for 21 days, and then the ectopic lesions were harvested for analyses. All experiments were repeated at least three times.
Statistical Analysis. Statistical analysis was performed using a paired Student t test in GraphPad Prism 5.00 (GraphPad, La Jolla, CA).
Results
Corepressor Components Recruitment to ERa by TSEC. The physical and functional interactions between ERa and its coregulators are essential for the regulation of ERa-mediated transcription upon estrogenic stimulation (Foulds et al., 2013) . In this regard, ERa recruits different coregulators to regulate target gene expression upon various external stimuli (Foulds et al., 2013) . Therefore, we hypothesized that the TSEC should generate unique ERa-coregulator combinations to confer endometrial and breast safety. ERa activity determined by PR expression in HeLa cells transfected with human ERa expression vector revealed that 10 nM CE stimulated ERa, activity and 100 nM, but not 10 nM, BAZ inhibited ERa activity that was stimulated by CE (Supplemental Fig. 1 ). To examine the coregulators bound to ERa upon CE, BAZ, and TSEC treatment, ERa-ERE pull-down assays were performed using a biotinylated DNA fragment containing the ERE in HeLa cell nuclear extracts (Foulds et al., 2013) . Compared with vehicle, 10 nM CE also actively enhanced interaction of ERa with steroid receptor coactivators (SRCs), and this CE-mediated interaction was strongly inhibited by 100 nM, but not 10 nM, BAZ (Supplemental Fig.  2, A and B) . Interestingly, the amount of SRCs recruited to ERa by 10 nM CE was less than by 10 nM E2. Therefore, the reduced amounts of coactivator recruitments to ERa might provide the lesser estrogenic activity of CE compared with estradiol. Based on these observations, 10 nM CE plus 100 nM BAZ combinations have been applied as a TSEC in this study. The proteins that coprecipitated with ERa in response to each hormone were identified by mass spectrometric analyses (Fig.  1A) . Compared with other hormone treatments, CE treatment enhanced the recruitment of transcriptional coactivators (such as SRCs, NCoA6, RAD50, and Mediator complex components) to ERa bound to the ERE DNA fragment (Fig.  1A) . Consistent with the mass spectrometry analyses, the ERa-ERE pull-down assays followed by Western blot analyses indicated that SRC-1, SRC-2, and SRC-3 were significantly recruited to ERa upon CE treatment compared with treatment with other agents (Fig. 1B) . However, less SRC-1, -2, and -3 was recruited to BAZ-and TSEC-bound ERa compared with CE treatment (Fig. 1, A and B) . Notably, the SRC expression levels in HeLa cells were not altered by CE, BAZ, or TSEC compared with vehicle treatment (Fig. 1, C-F) .
In contrast, the ERa-ERE pull-down assays coupled with mass spectrometric analyses revealed that TSEC treatment led to increased recruitment of different coregulators, usually transcriptional repressor components, such as BCOR and histone deacetylase3 (Fig. 1A) . The TSEC-induced recruitment of BCOR to ERa was confirmed using ERa-ERE pulldown assays followed by Western blotting analyses (Fig. 1B) . Collectively, the TSEC-induced recruitment of transcriptional repressors relative to transcriptional activators correlates Fig. 1 . Differential recruitment of coregulators to ERa upon CE, BAZ, and TSEC treatment. (A) ERa/ERE-DNA pull-down analyses were performed using HeLa nuclear extracts in the presence of vehicle, CE (10 nM), BAZ (100 nM), and TSEC (10 nM CE plus 100 nM BAZ) as described in Materials and Methods. Proteins associated with ERa after different hormone treatments were identified by MS analyses, and the peptide numbers were listed. (B) After ERa/ERE-DNA pull-down analyses, the levels of SRC-1, SRC-2, SRC-3, BCOR, and ERa in the precipitates were determined by Western blotting analyses. SRC-1 (C), SRC-2 (D), and SRC-3 (E) protein levels in HeLa cells treated with hormone for 24 hours were determined by Western blotting analyses (n = 3/group). The tubulin level in each group was used as a protein loading control. (F) The ratios of SRCs to tubulin levels in (C)-(E) are shown in a graph. NS, nonspecific, Student's t test. Values represent the average 6 S.E.M. of three independent experiments.
Dual Inhibition of ERa by Tissue-Selective Estrogen Complex
with inhibition of ERa target gene transcription in endometrial cells upon TSEC treatment.
Degradation of the Uterine ERa Protein by TSEC to Prevent Endometrial Stimulation. To analyze the endometrial effects of TSEC in more detail, uterotrophic assays were performed using ovariectomized female mice: on the 14th day after ovariectomy, the mice were randomly divided into four groups and then administered vehicle, CE (2.5 mg/kg), BAZ (2.5 mg/kg), or TSEC containing both CE (2.5 mg/kg) and BAZ (2.5 mg/kg) daily for 3 days. Six hours after the final hormone injection, uteri were isolated from each group of mice and weighed. Compared with vehicle treatment, CE treatment significantly increased uterine weight, but both BAZ and TSEC did not increase uterine weight (Fig. 2, A and B) . Unlike CE, therefore, BAZ and TSEC had no endometrial stimulatory effect (Fig. 2, A and B) . Furthermore, the presence of BAZ in the TSEC suppressed CE-mediated endometrial stimulation.
To elucidate the endometrial safety of TSEC, uterine ERa levels were measured in each hormone-treated group. Compared with vehicle treatment, CE, BAZ, and TSEC treatments reduced uterine ERa protein levels (Fig. 2, C and D) . To determine whether the reduction in ERa protein level was correlated with downregulation of the ERa mRNA level, uterine ERa mRNA levels were measured in each hormonetreated group. Notably, uterine ERa mRNA levels were not altered by hormone treatment compared with vehicle treatment (Fig. 2E) . Therefore, CE-mediated ERa degradation is associated with endometrial stimulation, an effect observed previously (Nawaz et al., 1999; Callige and Richard-Foy, 2006 ). However, TSEC-mediated ERa degradation occurred in the absence of endometrial stimulation in mice.
TSEC-Mediated ERa Degradation Prevents ERa Activity in Human Breast Cancer Cells. To examine the effect of TSEC on breast ERa, MCF7 human breast cancer cells were selected. Consistent with HeLa nuclear extracts, the ERa-ERE pull-down assays followed by Western blot analyses with MCF7 nuclear extracts indicated that coactivators (SRC-1 and SRC-3) were significantly recruited to ERa upon CE treatment compared with treatment with other agents (Fig. 3A) . In contrast to coactivators, BCOR (transcriptional repressor) and FBXO45 effectively interact with ERa upon TSEC treatment compared with other hormones in the MCF7 nuclear extracts (Fig. 3A) . Therefore, breast ERa has similar responses upon CE and TSEC treatment compared with endometrial ERa.
To investigate the effect of TSEC on breast ERa protein levels, MCF7 human breast cancer cells were treated with CE (10 mM), BAZ (100 mM), or TSEC (containing CE and BAZ) for 1 day. Subsequently, the ERa protein level in each group of cells was determined by Western blot analysis. Consistent with endometrial ERa expression, the breast ERa levels in MCF7 cells were significantly reduced by CE, BAZ, and TSEC treatment compared with vehicle treatment (Fig. 3, B and C) . Breast ERa RNA levels in MCF7 cells were not altered by CE, BAZ, or TSEC treatment compared with vehicle treatment (Fig. 3D) . These data indicate that CE and TSEC also cause degradation of the ERa protein in breast cancer cells.
To explain the functional correlation between ERa degradation and ERa activity in breast cancer cells, we measured levels of PR because PR is the direct ERa target gene (Nagai and Brentani, 2008) . Compared with vehicle treatment, CE treatment increased PR mRNA levels in MCF7 cells, whereas BAZ and TSEC treatment did not (Fig. 3E) . Therefore, similar to the endometrial data, CE-mediated ERa degradation was associated with induction of ERa activity, whereas BAZ-and TSEC-mediated ERa degradation correlated with suppression of ERa activity in MCF7 cells.
The SERMs, BAZ, and tamoxifen inhibit ERa activity in breast cancer cells (Lewis-Wambi et al., 2011; Cirillo et al., 2013) . However, these drugs inhibit ERa activity through different mechanisms. For example, the 4-hydroxytamoxifenmediated inhibition of ERa activity was not associated with a reduction in ERa protein levels in MCF-7 cells compared with vehicle treatment (Fig. 3, F and G) . Therefore, these data indicate that a unique ERa destabilization activity of BAZ and TSEC effectively downregulates ERa activity in both endometrial and breast cells.
To determine whether this unique molecular property of TSEC correlates with tissue specificity, ERa levels in bone cells (HTB-85, osteosarcoma) were determined upon each treatment. In contrast to endometrial and breast cells, CE, BAZ, and TSEC did not reduce ERa levels in HTB-85 cells compered to vehicle treatment (Fig. 3, H and I) . Interestingly, BAZ and TSEC led to a small increase in ERa levels in bone cells compared with vehicle and CE treatment. We conclude that TSEC treatment differentially modulates the ERa protein level in a tissue-specific manner.
Interaction of ERa with FBXO45 upon TSEC Treatment. Our data revealed that CE-and TSEC-mediated ERa degradation was associated with differential cellular regulation of ERa activity (Figs. 2 and 3 ). This observation suggests that distinct proteasome complexes might be involved in CEversus TSEC-mediated ERa degradation. To test this hypothesis, we analyzed whether the ubiquitination-dependent proteasome might be differentially recruited during CEversus TSEC-mediated ERa degradation. In the presence of DMSO, CE, BAZ, and TSEC treatments, but not vehicle treatment, ERa protein degradation occurred in HeLa cells (Fig. 4A) . However, all of these ERa degradations were prevented by the addition of the proteasome inhibitor MG132 (Fig. 4B) . Therefore, both CE-and TSEC-induced ERa protein degradations require a ubiquitin-dependent proteasome system.
The ubiquitin-dependent proteasome systems consist of several components that are involved in specific cellular processes (Devoy et al., 2005; Konstantinova et al., 2008) . Therefore, we analyzed whether different components of the ubiquitin proteasome complex might be involved in CEversus TSEC-mediated ERa degradation. ERE-DNA pulldown assays coupled with mass spectrometry analyses revealed that FBXO45, a component of an E3 ubiquitin ligase complex (Saiga et al., 2009; Tada et al., 2010) , was significantly recruited to the ERa/ERE complex in the presence of TSEC compared with vehicle (Fig. 4, C and D) . However, less FBXO45 protein was recruited to the ERa/ERE complex upon E2 or CE treatment compared with TSEC treatment ( Fig. 4D;  Supplemental Fig. 2C ). BAZ did not stimulate FBXO45 recruitment to the ERa/ERE complex compared with vehicle (Fig. 4D) . Immunoprecipitation with HeLa cells transfected with ERa and/or Flag-tagged FBOX45 cDNA using Flag antibody also revealed the interaction of FBXO45 with ERa in the presence of MG132 (Fig. 4E) . To test whether this interaction was enhanced by TSEC treatment, HeLa cells were transiently transfected with expression vectors for ERa Fig. 2 . TSEC causes ERa protein degradation in murine uteri to prevent ERa-mediated endometrial stimulation. (A) Uteri were isolated from ovariectomized mice treated daily with vehicle, CE (2.5 mg/kg), BAZ (2.5 mg/kg), and TSEC (2.5 mg/kg CE plus 2.5 mg/kg BAZ) for 3 days, and then uterine morphology was examined. (B) The uterine wet weights in each group described in (A) are shown in a graph (n = 4/group). (C) ERa and tubulin (loading control) protein levels in the uteri in (A) were determined by Western blotting analyses (n = 3/group). (D) The ratios of ERa to tubulin levels in (C) are shown in a graph (n = 3/group). (E) ERa mRNA and 18S rRNA levels in the uteri in (A) were measured. The relative ERa mRNA levels in each hormone-treated uterus were determined as compared with the RNA levels in the vehicle-treated group after normalization with 18S rRNA levels. **P , 0.01; ***P , 0.001. NS, nonspecific versus control, Student's t test. Values represent the average 6 S.E.M. of three independent experiments.
and Flag-tagged FBXO45, and then treated with vehicle, CE, BAZ, or TSEC. Flag-tagged FBXO45 was then immunoprecipitated using the Flag antibody, and ERa levels in the precipitated pellets were determined using Western blot analyses. Consistent with the results of the ERE-DNA pulldown assay (Fig. 4C) , the interaction of ERa with FBXO45 was enhanced by TSEC treatment compared with vehicle and CE treatment (Fig. 4F) . In addition, BAZ treatment also enhanced the interaction of ERa with FBXO45 compared with vehicle and CE in HeLa cells (Fig. 4F) . This BAZ-mediated interaction Fig. 3 . TSEC causes ERa protein degradation in human breast cancer cells to inhibit ERa activity. (A) ERa/ERE-DNA pull-down analyses were performed using MCF7 nuclear extracts in the presence of vehicle, CE (10 nM), BAZ (100 nM), and TSEC (10 nM CE plus 100 nM BAZ). After ERa/ ERE-DNA pull-down analyses, the levels of SRC-1, SRC-3, FBXO45, BCOR, and ERa in the precipitates were determined by Western blotting analyses. (B) MCF7 cells were treated with vehicle, CE (10 nM), BAZ (100 nM), and TSEC (10 nM CE and 100 nM BAZ) for 24 hours. Subsequently, the ERa and tubulin protein levels in MCF7 cells were determined by Western blotting analyses (n = 3/group). (C) The ratios of ERa to tubulin in the MCF7 cells in (B) are shown in a graph (n = 3/group). (D) The total RNA was isolated from the MCF7 cells in (B), and the levels of ERa mRNA and 18S rRNA were determined by real-time reverse-transcription polymerase chain reaction analyses. The ERa mRNA levels in each group were normalized to the 18S rRNA levels. The normalized ERa mRNA levels in hormone-treated MCF7 cells relative to vehicle-treated MCF7 cells are shown in a graph (n = 3/group). (E) PR mRNA levels were determined in the MCF7 cells described in (B) and normalized to the 18S rRNA levels. The normalized PR mRNA levels in hormone-treated MCF7 cells relative to vehicle-treated MCF7 cells are shown in a graph (n = 3/group). (F) MCF7 cells were treated with vehicle, CE (10 nM), 4-hydroxytamoxifen (4-HT; 100 nM), and CE (10 nM) plus 4-HT (100 nM) for 24 hours. Subsequently, the ERa and tubulin protein levels were determined by Western blotting analyses (n = 3/group). (G) The ratio of ERa to tubulin in (F) is shown in a graph. (H) HTB-85 cells were treated with vehicle, CE (10 nM), BAZ (100 nM), and TSEC (10 nM CE plus 100 nM BAZ) for 24 hours. Subsequently, the ERa and tubulin protein levels in HTB-85 cells were determined by Western blotting analyses (n = 2/group). (I) The ratios of ERa to tubulin in the HTB-85 cells are shown in a graph (n = 3/group). *P , 0.05; **P , 0.01; ***P , 0.001; NS, not significantly different versus vehicle, Student's t test. Values represent the average 6 S.E.M. of three independent experiments. of ERa with FBXO45 was not detected using the ERE-DNA pull-down assay (Fig. 4D) . Therefore, these data indicate that the FBXO45/ubiquitin proteasome complex interacts with ERa only upon TSEC treatment in ERE-DNA.
Degradation of the ERa Protein by the FBOX45/ Ubiquitination by TSEC. TSEC induced an interaction of ERa with FBXO45. Next, we analyzed whether this interaction is directly correlated with TSEC-induced ERa degradation. HeLa cells were transiently transfected with ERa and different amounts of FBXO45 expression vectors, and the ERa protein levels were determined by Western blot analyses. The ERa protein levels gradually decreased in the presence of increased FBXO45 levels compared with cells transfected with the empty expression vector (Fig. 5A) . However, PR protein levels were not reduced in the presence of higher FBXO45 levels (Fig. 5A) . Therefore, elevation of the FBXO45 level caused the specific degradation of ERa, but not PR, in HeLa cells.
The effects of FBXO45 gain-of-function and loss-of-function in TSEC-induced ERa degradation were examined with HeLa cells transfected with ERa. To reduce FBXO45 protein levels in HeLa cells, the cells were treated with siRNA targeting FBXO45. As a control, HeLa cells were treated with nontargeting siRNA (NT-siRNA). Subsequently, both groups of cells were treated with vehicle, CE, BAZ, or TSEC to test their effects on ERa degradation. After hormone treatment, the ERa and FBXO45 protein levels in both groups of HeLa cells were determined by Western blotting analyses. FBXO45 levels were significantly reduced by FBXO45 siRNA compared with NT-siRNA in HeLa cells (Fig. 5B) . In the NT-siRNAtreated HeLa cells, ERa protein levels were reduced by CE, BAZ, and TSEC treatments compared with the vehicle (Fig.  5B) . However, BAZ and TSEC treatment did not reduce ERa protein levels in FBXO45 siRNA-treated cells compared with the vehicle (Fig. 5B) . Notably, CE treatment reduced the ERa protein level in FBXO45 siRNA-treated HeLa cells compared with vehicle treatment (Fig. 5B) . Therefore, FBXO45 is required for TSEC-mediated degradation, whereas it is not involved in CE-mediated ERa degradation in HeLa cells.
To examine whether increased FBXO45 expression degrades ERa protein in a TSEC-dependent manner, HeLa cells were transiently transfected with expression vectors for ERa and FBXO45. Subsequently, the cells were stimulated with vehicle, CE, BAZ, or TSEC, and then the ERa protein levels in these cells were determined by Western blot analysis. The ERa protein levels were not significantly reduced 9 hours after CE treatment compared with vehicle treatment (Fig. 5, C and  D) . BAZ treatment does not reduce ERa protein levels compared with vehicle treatment at 9 hours after treatment (Fig. 5, C and D) . However, ERa protein levels were rapidly and significantly reduced by TSEC treatment compared with vehicle treatment (Fig. 5, C and D) . Therefore, overexpressing FBXO45 effectively caused ERa protein degradation upon treatment with TSEC, but not with other agents.
Suppression of Ectopic Lesion Growth in Mice with Endometriosis by TSEC. Endometriosis is an estrogendependent disease, because estrogen signaling plays an essential role in the pathogenesis of endometriosis (Bulun, 2009) . Studies using ERa knockout mice with surgically induced endometriosis revealed that ERa has an essential role in the growth of ectopic lesions . Since the TSEC/FBXO45 axis is involved in ERa degradation in endometrial tissues (Fig. 5) , TSEC might be applied for an alternative endometriosis treatment, because TSEC minimizes the side effects of systemic estrogen-deficiency therapy in other estrogen target tissues, such as brain and bone, during treatment. To test this hypothesis, mice with surgically induced endometriosis were administered CE, BAZ, and TSEC. CE treatment increased the volume of the ectopic lesion in mice with endometriosis compared with vehicle treatment, most likely due to its endometrial stimulatory effect (Fig. 6, A and B) . However, compared with vehicle treatment, BAZ and TSEC did not stimulate ectopic lesion growth in mice with endometriosis (Fig. 6, A and B) . The presence of BAZ in TSEC suppressed the CE-mediated ectopic lesion growth during endometriosis. In addition, histologic analyses revealed that CE-treated ectopic lesions had well developed cyst formation (Fig. 6C ). This endometriotic cyst formation was not well developed in ectopic lesions treated with BAZ and TSEC as compared with CE-treated ectopic lesions (Fig. 6C) . In addition to the cyst formation, immunohistochemistry (IHC) analyses with Ki-67 antibody revealed that proliferative activities in epithelial and stromal compartments of ectopic lesions treated with BAZ and TSEC were significantly reduced compared with ectopic lesions treated with CE (Fig. 6D) . Collectively, TSEC treatment inhibited proliferative activity of ectopic lesions to prevent their progression, whereas CE promoted proliferative activity of ectopic lesions for the establishment of ectopic lesions.
Since TSEC degrades ERa protein to suppress ERa-mediated signaling in endometrial tissues (Fig. 2) , we analyzed whether TSEC caused the degradation of ERa in ectopic lesions to inhibit the estrogen-dependent growth of these lesions. ERa levels in ectopic lesions were determined by IHC analyses using an ERa antibody. TSEC-treated ectopic lesions had lower ERa protein levels in both epithelial and stromal compartments of ectopic lesions compared with CE-treated ectopic lesions (Fig. 6E) . Notably, IHC and Western blot analyses using an FBXO45 antibody revealed that FBXO45 levels were elevated in BAZ-and TSEC-treated ectopic lesions compared with CE-treated lesions (Fig. 6, F and G) , and TSEC-mediated elevation of FBXO45 levels appears to enhance TSECinduced ERa degradation to suppress the growth of ectopic lesions. Together, our data suggest that TSEC-induced ERa degradation in the endometrium might be used as an alternative endometriosis treatment to minimize the side effects of estrogen deprivation in other estrogen target tissues that are associated with certain current endometriosis treatments.
Discussion
Hormone replacement therapy has been used for the treatment of postmenopausal symptoms. To maximize the immunoprecipitated from each group, and the ERa levels in the immunoprecipitates were determined by Western blotting analyses. ***P , 0.001, Student's t test. Values represent the average 6 S.E.M. of three independent experiments. FBX, F-Box; IB, Immuno Blot assay; IP, immunoprecipitation; NS, not significantly different versus vehicle; RING, Really Interesting New Gene; UBI, Ubiquitin; UPS, Ubiquitin Proteasome System. benefits of hormone replacement therapy, TSEC was developed, which is a new menopausal therapy that combines a SERM with one or more estrogens. The goal of TSEC therapy is to reduce menopausal symptoms (e.g., hot flashes and vulvar/vaginal atrophy), prevent osteoporosis, and improve lipid parameters while inhibiting estrogenic stimulation of the breast and endometrium.
Although TSEC is known to inhibit estrogenic stimulation in the breast and endometrium, the molecular mechanisms underlying this function of TSEC were not understood. Here, we observed two new molecular mechanisms by which TSEC confers endometrial and breast safety effects. First, TSEC recruited corepressors, rather than coactivators, to ERa. In contrast, however, CE actively recruited coactivators to ERa compared with vehicle treatment, leading to enhanced ERa activity. The differential recruitment of ERa coregulators by CE versus TSEC is likely associated with distinct ERa conformational changes induced by these agents. For example, in the presence of a single hormone (such as CE and BAZ), each hormone-bound ERa generates homodimer binding to EREs to regulate ERa target genes. In the presence of TSEC, however, one agonist (CE)-bound ERa monomer binds to an antagonist (BAZ)-bound ERa to generate a distinct heterodimeric ERa conformation, which then binds to ERa target genes (Liu et al., 2013) . This unique heterodimeric ERa conformation generated by TSEC appears to induce an interaction of ERa with certain corepressors, leading to inhibition of ERa activity.
In addition, TSEC induced ERa degradation via the FBXO45/ubiquitin proteasome, leading to suppression of ERa activity in endometrial and breast cells. CE also induced the degradation of ERa in endometrial and breast cancer cells HeLa cells transfected with ERa were treated with 100 nM nontargeting siRNA or FBXO45 siRNA for 3 days followed by vehicle, CE (10 nM), BAZ (100 nM), and TSEC (10 nM CE and 100 nM BAZ) for 24 hours. Subsequently, the ERa, FBXO45, and tubulin protein levels in each group were determined by Western blotting analyses. (C) HeLa cells were transfected with expression vectors for ERa and FBXO45. The cells were then treated with vehicle, 10 nM CE, 100 nM BAZ, or TSEC (10 nM CE plus 100 nM BAZ) for 0, 1, 3, 6, and 9 hours. Subsequently, the ERa, FBXO45, and tubulin protein levels in each group were determined by Western blotting analyses. (D) Quantification of ERa levels in panel C is shown in the graph. hs, hours; RF, relative fold compared with control. , ERa (E), and FBXO45 (F) in each type of ectopic lesion described in (A) were determined using immunohistochemistry and are shown in the graph (n = 9/group). (G) Expression levels of FBXO45 in eutopic endometrium treated with each hormone were determined using Western blot analyses and are shown in the graph. *P , 0.05; **P , 0.01; ***P , 0.001. NS, nonspecific versus control, Student's t test.
by the ubiquitin-dependent proteasome. However, each hormone-induced ERa degradation was accompanied by an opposite effect on ERa activity: TSEC-induced ERa degradation was associated with inhibition of ERa activity, whereas CE-mediated ERa destabilization was correlated with enhancement of ERa activity. Previous studies also revealed that enhanced estradiol-induced ERa activation is associated with ERa degradation (Wijayaratne and McDonnell, 2001; Callige and Richard-Foy, 2006) , and a specific E3 ubiquitin ligase, such as E6-AP, might be involved in this process (Li et al., 2006; Sun et al., 2012) . However, the molecular mechanism underlying the functional correlation between estrogen-induced ERa degradation and ERa activation has not been fully elucidated. BAZ also causes ERa protein degradation similar to CE. However, BAZ-mediated ERa degradation is linked to the prevention of expression of ERa target genes, such as cyclin D1, in MCF-7:5C cells (LewisWambi et al., 2011) . The mechanism underlying BAZ-induced ERa degradation has not been investigated.
TSEC significantly reduced CE-mediated enhancement of ERa activity in endometrial and breast cancer cells by degrading ERa protein, in contrast with the E2-induced interaction of ERa with E6-AP for the ERa activation (Sun et al., 2012) . However, TSEC caused a differential interaction of ERa with FBXO45 for the suppression of ERa activity. FBXO45 modulates the stability of key factors that are involved in the regulation of cell-cycle arrest and apoptosis in response to DNA damage-induced cellular stress by its ubiquitin ligase activity (Melino, 2003) . For example, FBXO45 promotes the proteasome-dependent degradation of p73 to promote cell survival (Peschiaroli et al., 2009; Tada et al., 2010) . In the case of TSEC treatment, FBXO45/ubiquitin proteasome promoted ERa degradation to suppress ERa activity leading to suppression of endometrial stimulation effects. The unique heterodimeric ERa conformation induced by TSEC appears to generate a specific interaction with FBXO45 (Liu et al., 2013) . Collectively, TSEC treatment effectively prevents ERa activity by dual synergistic effects: recruitment of corepressors to ERa at target gene promoters and degradation of the ERa protein by a FBXO45/ubiquitin proteasome system in endometrial and breast cells.
Current endometriosis treatments induce systemic estrogen deficiency caused by the gonadotropin-releasing hormone agonists depot medroxyprogesterone acetate and danazol; aromatase inhibitors also are used (Telimaa et al., 1987; Haney and Weinberg, 1988; Telimaa, 1988; Fedele et al., 2000; Vigano et al., 2003; Selak et al., 2007) . However, these estrogen-deficiency therapies can have harmful side effects in other estrogen target tissues, such as the brain and bone in young reproductive-age women (Compston et al., 1995; Vanderschueren et al., 1997; Hughes et al., 2007) . Therefore, alternative endometriosis therapies that have fewer side effects in estrogen target tissues are needed. In this context, TSEC is an appropriate candidate for the next generation of endometriosis therapy because it effectively degrades ERa in endometriotic tissues but not in other estrogen target tissues, such as bone. Consistent with our study, other murine endometriosis models also revealed that TSEC effectively suppresses mouse endometriotic lesion growth compared with controls (Naqvi et al., 2014) . Collectively, TSEC treatment should have selective therapeutic effects in endometrial tissues by virtue of its synergistic dual ERa inhibitory effects.
